Hide Board Information

Show Board Information

ABLYNX (D) ABLX

Board Mod: Add me as mod

Asst Mods:

Last Post: 06/04/2012 1:52:35 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 3

ABLYNX (Euronext Brussels:ABLX)

ABLYNX is a biopharmaceutical company engaged in the discovery and development of Nanobodies ^® , a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease.

Company Website: http://www.ablynx.com/

ABLYNX (D) (ABLX) Stock Message Board

Find ABLX Recent News, ABLX Filings, ABLX Stock Quote, ABLX Stock Chart, ABLX Research & Opinions Below

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

Be the first to post on ABLYNX (D) ABLX

Recent Articles

• Explore Veza's Revolution in Just-in-Time Access Solutions
• Planar Launches New CarbonLight Series for Enhanced Visuals
• F5 Strengthens Leadership with John Maddison's Appointment
• Fnac Darty's Strategic Offer for Unieuro Shares Explained
• Pivotal Partners with Rosalynn Carter Institute for Caregivers
• NEO Battery Materials Ensures Operations Amid Political Turmoil
• Amaroq Minerals Launches Fundraising Initiative for Growth
• Exploring AI and Game Development at The Summit in New York
• Unlock Holiday Magic with Verizon's Exciting Deals This Season
• Harvest ETFs Boosts Monthly Cash Distribution Payments
• Casino Group's Asset Sale: A Strategic Financial Move
• Transflo Introduces Wallet Fuel Card for Trucking Efficiency
• Wynnchurch Capital Sells TH Holdings: Strategic Milestone Achieved
• Nitrogen Launches Innovative Product for Asset Managers' Engagement
• Acumen Velocity Introduces Document Translation Services
• Bridge Growth Partners' Successful Sale of Syniti to Capgemini
• BMO's Generous $7.5 Million Donation to United Way Initiative
• Herbalife Family Foundation Donates $5 Million for Global Change
• Pivot Bio Welcomes Melih Keyman to Board, Enhancing Expertise
• Navigating California’s Staffing Challenge: 2025 Insights
• Barbara Sinatra Children's Center Expands Services for Youth
• Unmissable Ticket Deals for Disneyland Resort Adventures
• Discover MicroBT's M66S Boosted by Rosseau's Cooling Tech
• Hublot Honors OpusX with Exclusive Classic Fusion Timepiece
• San Manuel Band's Generous Grants Aid Wildfire Recovery Efforts
• StockX Achieves Unprecedented Sales During Holiday Season
• Key HR Trends for 2025: Insights for Professionals and Leaders
• Exploring the Growth of the Industrial Absorbent Sector
• ACE Cash Express' Heartfelt Effort: $25K for Autism Speaks
• Celebrating Excellence: GovCIO Recognized for Impactful Services
• OSS Expands Cash Management Services Across the United States
• EverCharge Strengthens EV Charging with Advanced Risk Management
• Financial Recovery on the Rise: Challenges and Solutions for Survivors
• Everclear's Mainnet Beta Shines with New Tokenomics Plans
• URW SE Updates: Voting Rights and Shares Overview
• Sodexo's Recent Share Transactions and Company Insights
• ISS A/S Welcomes New Employee Representative on Board
• Kering Announces Interim Dividend for 2024 Financial Year
• Coface SA Updates Total Voting Rights and Share Capital Details
• Capgemini Enhances Data Transformation with Syniti Acquisition
• Understanding TOUAX's Share Capital and Voting Rights Overview
• Understanding Voting Rights and Their Importance for Shareholders
• Sean Hannity Launches Interview Show 'Sean' on FOX Nation
• LVMH Announces Important Share Transactions for November
• Introducing Salgenx's Innovative Saltwater Battery Solution
• AWS Introduces Powerful Trainium2 Instances for AI Workloads
• Acathia Capital Strengthens Investment in Leading Savings Platform
• Amazon S3 Unleashes New Features for High-Performance Data Lakes
• Uncovering the Explosive Expansion of the Resistant Starch Market
• ivWatch Honored in Inc.'s 2024 Best in Business Awards